MONTREAL, Oct. 10 /CNW/ - ConjuChem Biotechnologies Inc. (TSX:CJB) today
announced that dosing has been initiated in its Phase I/II multiple-dose
clinical study for the treatment of Type 2 diabetes using the Company's
proprietary PC-DAC(TM):Exendin-4.
